Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma
about
Bending the Cost Curve in Cancer CaremichGranulopoiesis-stimulating factors for preventing infections after autologous peripheral stem cell transplantation for lymphoma and multiple myeloma in adultsIntravenous immunoglobulins for the treatment of infections in patients with haematological cancersGranulopoiesis-stimulating factors for preventing infections after autologous peripheral stem cell transplantation for lymphoma and multiple myeloma in adultsQ24235340Intravenous immunoglobulins for the treatment of infections in patients with haematological cancersProphylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapyAntibiotics plus colony stimulating factors versus CSFs alone and antibiotics plus CSFs versus no prophylaxis for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationBiosimilars in the management of neutropenia: focus on filgrastimManagement of neutropenic patients in the intensive care unit (NEWBORNS EXCLUDED) recommendations from an expert panel from the French Intensive Care Society (SRLF) with the French Group for Pediatric Intensive Care Emergencies (GFRUP), the French SProphylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?Infection is an Independent Predictor of Death in Diffuse Large B Cell Lymphoma.Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trialAdvances in the treatment of neutropenia.Comparison of Therapeutic G-CSF Cycles and Prophylactic G-CSF Cycles in Patients Receiving Paclitaxel and Carboplatin Combination Chemotherapy for Ovarian Cancer: A Retrospective Study ReportNeutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin LymphomaFludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia.Colony-stimulating factors for chemotherapy-related febrile neutropenia are associated with improved prognosis in adult acute lymphoblastic leukemiaThe glutathione disulfide mimetic NOV-002 inhibits cyclophosphamide-induced hematopoietic and immune suppression by reducing oxidative stress.Efficacy and safety of acupuncture for chemotherapy-induced leucopoenia: protocol for a systematic review.A way forward on the medically appropriate use of white cell growth factorsA Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and DocetaxelImpact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia.Retinoid agonist Am80-enhanced neutrophil bactericidal activity arising from granulopoiesis in vitro and in a neutropenic mouse model.Am80-GCSF synergizes myeloid expansion and differentiation to generate functional neutrophils that reduce neutropenia-associated infection and mortality.Colony-stimulating factors for febrile neutropenia during cancer therapy.Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia.Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.The immune system's role in sepsis progression, resolution, and long-term outcome.Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cPrimary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis.Re: personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity.Model-based optimization of G-CSF treatment during cytotoxic chemotherapy.
P2860
Q22248106-33028D34-B2D0-4307-8197-2528884812CDQ24186266-5698D746-46F8-4DAE-A508-1C2ED4B4FCB7Q24186274-16544088-2139-4158-B5C8-0430132BF2D3Q24200850-03B0FD4A-E05C-4F32-B5BF-444D6166FFA6Q24235340-C21DBFCF-DE4A-4982-8356-B97907EE3130Q24236448-17BACA2E-32AB-49F8-9805-CD808BA5906CQ24241680-DE64BD41-32C6-4111-AF64-453D5724B572Q24241689-8A3C7B72-D0A4-4444-A4E9-C778CC041BD8Q26764906-D6ECBFEC-ADFC-495A-A6EC-43870359D781Q27320711-B4BE1988-65B9-474E-B316-2CBFD9793952Q33756369-D4E94115-2D31-414D-8DFF-6F8BF1FB1780Q33861071-20370E6A-96BF-4557-8880-25ED585CF8AFQ34013208-3B604DE1-B4EF-480A-8B9D-3FDD8C134CFEQ34609244-ABCE3323-7E1F-4A0A-9762-04B6C703C02DQ35025491-05ED7804-1FC4-4CA7-B807-252C2A8E3B8BQ35038832-6BBA0E0B-DBE6-4EBD-9E61-A75097447970Q35806293-A1E0044E-F4BB-477C-BFE4-F39B843D22B1Q35809788-F0859661-45B6-469A-B19D-31451DEDB4E3Q35925964-69E5DB35-5C51-4C68-A641-4F56F049F3DCQ36031915-A6DF8030-5920-4A67-8EF6-7D76B9FF795CQ36058245-756192D7-052E-4035-BF03-5F741731D44CQ36452230-E0CC1E7F-7012-4AF7-B72D-EFE301E29A44Q36498360-BA577E8B-DAF2-4843-9FD7-B72B6FBC947EQ36595328-6A5631D3-C835-4C4C-B5C7-DDABE1B218F0Q37387000-05633426-5505-46FC-9C78-17CA28E12D08Q37626772-15F01D77-2EA9-47CE-B74F-124C4E7BEC05Q38256944-7F6414EC-E0A9-40FB-A8E1-382353AA9C96Q38682028-CE251700-35A2-4143-BE22-77ADD5DDFFB1Q38991057-461090E3-0541-4AD2-9F6D-D8E37CF353DFQ40274712-FEE963C3-26D6-43A4-A518-9F8625644B50Q42540897-494059E3-5F04-4CC1-BF43-96CCEA92811EQ43026530-51D43B74-76FE-4EFE-91B8-90E565D6FF0BQ45746480-0DE603B9-1C77-4352-90E9-AC9BA609E268Q47657705-3430267A-FD31-4249-9F4C-FAB4E98708A3
P2860
Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma
description
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
article scientifique (publié 2008/10/08)
@fr
articolo scientifico (pubblicato il 2008/10/08)
@it
artigo científico (publicado na 2008/10/08)
@pt
artikull shkencor
@sq
artículu científicu espublizáu en 2008
@ast
scientific article (published 2008-10-08)
@en
vedecký článok (publikovaný 2008/10/08)
@sk
videnskabelig artikel (udgivet 2008/10/08)
@da
name
Granulopoiesis-stimulating fac ...... reatment of malignant lymphoma
@ast
Granulopoiesis-stimulating fac ...... reatment of malignant lymphoma
@en
Granulopoiesis-stimulating fac ...... reatment of malignant lymphoma
@en-gb
Granulopoiesis-stimulating fac ...... reatment of malignant lymphoma
@nl
type
label
Granulopoiesis-stimulating fac ...... reatment of malignant lymphoma
@ast
Granulopoiesis-stimulating fac ...... reatment of malignant lymphoma
@en
Granulopoiesis-stimulating fac ...... reatment of malignant lymphoma
@en-gb
Granulopoiesis-stimulating fac ...... reatment of malignant lymphoma
@nl
prefLabel
Granulopoiesis-stimulating fac ...... reatment of malignant lymphoma
@ast
Granulopoiesis-stimulating fac ...... reatment of malignant lymphoma
@en
Granulopoiesis-stimulating fac ...... reatment of malignant lymphoma
@en-gb
Granulopoiesis-stimulating fac ...... reatment of malignant lymphoma
@nl
P2860
P50
P3181
P1476
Granulopoiesis-stimulating fac ...... reatment of malignant lymphoma
@en
P2093
Christine Herbst
Marcel Reiser
P2860
P3181
P356
10.1002/14651858.CD003189.PUB4
P577
2008-10-08T00:00:00Z